Julie Ostrander

Associate Professor of Medicine, Division of Hematology, Oncology and Transplantation
Faculty, MS and PhD Programs in Molecular Pharmacology and Therapeutics (MPaT)
Faculty, Masonic Cancer Center (MCC)


Administrator Info
Lab Phone: 612-624-8201
Phone: 612-626-5475
Email: mccadmin@umn.edu
Mail: Cancer and Cardiovascular Research Building
1st Floor Mailroom CCRB
2812A (Campus Delivery Code)
2231 6th St SE
Minneapolis, MN 55455

Julie Ostrander, Ph.D. is an Assistant Professor in the Department of Medicine at the University of Minnesota and a member of the Cellular Mechanisms of Cancer Program at the University of Minnesota Masonic Cancer Center. Dr. Ostrander received her Ph.D. from the University of North Carolina at Chapel Hill. She holds memberships in the American Association for Cancer Research and the Endocrine Society.

Research Summary

Dr. Ostrander's research focuses on studying the scaffolding protein PELP1 in the context of breast cancer progression. Our recent studies have found that PELP1 signaling 1) promotes cell survival in the presence of tamoxifen, 2) enhances breast epithelial cell migration through upregulation inflammatory cytokines and chemokines, and most recently 3) promotes CSC phenotypes in models of ER-positive breast cancer. We have identified a novel cytoplasmic interaction between PELP1 and SRC-3. The objective of our current research is to identify the molecular mechanisms associated with PELP1-induced BCSC phenotypes and therapy resistance.

Research Interest: Solid Tumors

Professional Memberships

Cellular Mechanisms
American Association of Cancer Research (AACR)
Masonic Cancer Clinic
Endocrine Society
Selected Publications

Selected Publications

Girard BJ, Knutson TP, Kuker B, McDowell K, Schwertfeger KL, Ostrander JH. Cytoplasmic Localization of Proline, Glutamic Acid, Leucine Rich Protein 1 (PELP1) Induces Breast Epithelial Cell Migration through Upregulation of Inhibitor of kappa B Kinase Epsilon and Inflammatory Crosstalk with Macrophages. J Biol Chem. 2017;292(1):339-350.,
Truong TH, Hu H, Temiz NA, Hagen KM, Girard BJ, Brady NB, Schwertfeger KL, Lange CA*, and Ostrander JH* Cancer Stem Cell Phenotypes in ER+ Breast Cancer Models Are Promoted by PELP1/AIB1 Complexes. Molecular cancer research. 2018;16(4):707-719. *Denotes co-principal investigators,
Regan Anderson, TM, Ma S, Perez Kerkvliet, C, Peng, Y, Helle, TM, Krutilina, RI, Raj, GV, Cidlowski, JA, Ostrander, JH, Schwertfeger, KL, Seagroves, TN, Lange, C.A. Taxol induces brk-dependent prosurvival phenotypes in TNBC cells through an AhR/GR/HIF-driven signaling axis. MCR; 2018; 16(11); 1761–72.,
Truong, TH, Lange, CA, Ostrander, JH. Targeting steroid receptor coactivators to inhibit breast cancer stem cells. Oncoscience. 201;5(11-12):281-282,
Dwyer AR, Truong TH, Ostrander JH, Lange CA. 90 YEARS OF PROGESTERONE: Steroid receptors as MAPK signaling sensors in breast cancer: let the fates decide. J Mol Endocrinol. 2020 Jul;65(1):T35-T48. doi: 10.1530/JME-19-0274. PubMed PMID: 32209723; PubMed Central PMCID: PMC7329584.,